LipoScience, which provides a diagnostic test to assess cardiovascular disease risk, raised $45 million on Thursday by offering 5 million shares at $9, 36% below the midpoint of the original $13-$15 range. The company cut its estimated price range to $9-$10 earlier on Thursday. LipoScience plans to list on the NASDAQ under the symbol LPDX. Barclays, UBS Investment Bank and Piper Jaffray acted as underwriters on the deal.
